Clinical Trials Directory

Trials / Terminated

TerminatedNCT00811915

Study to Compare the Safety and Efficacy of Sirolimus (Rapamune) to Tacrolimus (Advagraf) Associated to Mycophenolate Mofetil (CellCept) Between 12 and 36 Months After Kidney Transplantation

A Prospective, Comparative, Multicenter, Randomized Study to Compare the Safety and Efficacy of Sirolimus (Rapamune) to Tacrolimus (Advagraf) Associated to Mycophenolate Mofetil (CellCept) Between 12 and 36 Months After Kidney Transplantation

Status
Terminated
Phase
Phase 3
Study type
Interventional
Enrollment
65 (actual)
Sponsor
University Hospital, Rouen · Academic / Other
Sex
All
Age
18 Years – 76 Years
Healthy volunteers
Not accepted

Summary

The use of tacrolimus in the long term as part of the immunosuppressive regimen after transplantation is associated to complications such as chronic nephrotoxicity, impaired glucose metabolism (diabetes mellitus) and an increase of the incidence of neoplasia. The conversion from a tacrolimus based therapy to a sirolimus based therapy associated with mycophenolate mofetil could improve the incidence of such complications. The aim of this study is to assess the risk/benefit ratio of this switch performed in stable renal transplant recipient between 12 months and 36 months after transplantation. The incidence of a composite endpoint (worsening of GFR evaluated by MDRD formula, incidence of cancer and diabetes) will be assessed 24 months after conversion.

Detailed description

Two doses of Sirolimus will be evaluated accorded to the CYP 3A5 genotype. Patients carrying at least CYP 3A5 \*1 allele will receive 4 mg per day whereas the others (CYP 3A5 \*3/\*3) will receive 2 mg.

Conditions

Interventions

TypeNameDescription
DRUGSirolimusSirolimus introduction and tacrolimus withdrawal Tacrolimus : 33 % decrease of daily dose with complete withdrawal at day 14. Sirolimus daily dose according to CYP3A5 genotype CYP3A5\*1/\*1 or \*1/\*3: 4 mg/d CYPY3A5\*3/\*3 : sirolimus 2 mg/j Adjusted to obtain a trough level between 6 and10 ng/ml

Timeline

Start date
2009-01-01
Primary completion
2013-12-01
Completion
2014-06-01
First posted
2008-12-19
Last updated
2026-04-14

Locations

8 sites across 1 country: France

Source: ClinicalTrials.gov record NCT00811915. Inclusion in this directory is not an endorsement.